Strata Critical Medical (SRTA) UBS Global Technology and AI Conference summary

Business transformation and growth

• Transitioned from a helicopter airport shuttle to a leading urban air mobility ecosystem, focusing on infrastructure, technology, and brand strength in the US Northeast and Southern Europe.

• Achieved profitability in the passenger segment over a year ahead of guidance, emphasizing prudent, profitable growth.

• Medical transport business grew from $15M to $150M in three years, now the largest air transporter of human organs in the US.

• Asset-light model with only 10% of missions on owned aircraft, leveraging economies of scale between passenger and medical operations.

• Medical and passenger businesses operate synergistically but independently, supporting operational flexibility.

Medical transport and market expansion

• Medical business leverages relationships with top hospitals, expanding from helicopters to jets and ground vehicles, now moving organs, tissue, and blood samples.

• Holds 20% market share in current organ transport markets, with significant white space for growth.

• Growth drivers include new hospital contracts, pricing escalators, and adoption of perfusion devices that extend organ viability and trip distances.

• Organ matching services and new procedures like NRP are expanding the addressable market and increasing transplant success rates.

• Recent tuck-in acquisitions in ground transport and organ matching enhance service offerings and market share.

Technology and future opportunities

• Electric Vertical Aircraft (EVA/eVTOL) expected to unlock growth starting Q4 2025 in the Middle East and Q4 2026 in the US, enabling more landing zones and quieter, emission-free flights.

• Strategic alliances with OEMs and device manufacturers like OrganOx position the company to accelerate commercialization and infrastructure use.

• Regulatory progress, especially with the FAA, is key to mainstream adoption; streamlined certification could accelerate timelines.

• EVA introduction will initially maintain similar pricing to current helicopter services, with costs expected to decrease as technology matures.

• Plans to evolve into a broader asset-light logistics platform for time-sensitive critical cargo beyond medical, targeting new verticals like manufacturing and radioisotopes.